Loading clinical trials...
Loading clinical trials...
The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Abbott
NCT06967857 · Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder
NCT06577779 · Attention-deficit/Hyperactivity Disorder
NCT07379359 · Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT06798337 · Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT07044609 · Attention-deficit/Hyperactivity Disorder, Oppositional Defiant Disorder in Children
Site Ref #/Investigator 6800
Little Rock, Arkansas
Site Ref #/Investigator 6812
Boulder, Colorado
Site Ref #/Investigator 8366
Bradenton, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions